Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ACTRN12626000488303) titled 'A double-blind, placebo-controlled study to evaluate the safety, tolerability and potential antiseizure activity of adjunctive OV-329 in adult focal epilepsy patients' on April 20.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Ovid Therapeutics Australia Pty Ltd
Condition:
Epilepsy
Epilepsy
Neurological - Epilepsy
Intervention:
This phase II study aims to assess the safety, tolerability and pharmacokinetics of an investigational product -OV329 -as well as determining whether it reduces seizure frequency compared to baseline. OV329 w...